The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Dashboard: Filter Bricks
Main page content
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This Advisory is based on TIP 55, Behavioral Health Services for People Who Are Homeless. It addresses the fundamentals of how providers and administrators can employ approaches to address the complex challenges of providing integrated treatment services to clients experiencing homelessness.
This manual offers skills and resources to service providers working with people who are experiencing homelessness or at risk of homelessness. It outlines types of homelessness and stages of recovery, including substance use screening and supportive treatment. Access the literature review.
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.